Demarest K T, Riegle G D, Moore K E
Endocrinology. 1984 Aug;115(2):493-500. doi: 10.1210/endo-115-2-493.
The content of dopamine (DA) and the activity of beta-glucuronidase (a marker for lysosomal enzymes) in the anterior pituitary and the concentration of PRL in serum were determined in male rats that were treated with a variety of drugs that influence the release, storage, or actions of DA. Drugs that increase DA in hypophysial portal blood (amphetamine, methylphenidate and L-dopa) increased DA content, decreased PRL secretion, and had no effect on lysosomal enzyme activity. Drugs that activate DA receptors in the anterior pituitary (apomorphine and bromocriptine) decreased serum PRL but had no effect on DA content or lysosomal enzyme activity. Drugs that decrease DA in the hypophysial portal blood (alpha-methyltyrosine, gamma-butyrolactone, and reserpine) or block DA receptors (haloperidol) increased PRL secretion and decreased DA content and lysosomal enzyme activity. These results suggest that there is no obvious relationship between anterior pituitary DA content and PRL secretion. In addition, lysosomal enzyme activity is not stimulated by increasing the concentration of DA or activating DA receptors in the anterior pituitary, but lysosomal enzyme activity does appear to be tonically stimulated by DA in the control animals since decreasing DA concentrations or receptor activation in the anterior pituitary decreases beta-glucuronidase activity. This latter proposal was confirmed by the demonstration that apomorphine reduced the alpha-methyltyrosine-induced increase in serum PRL and prevented the decrease in anterior pituitary DA content and beta-glucuronidase activity. Furthermore, pretreatment with bromocriptine and L-dopa blocked both the increase in serum PRL concentration and the decrease in anterior pituitary DA content induced by alpha-methyltyrosine and gamma-butyrolactone. On the other hand, bromocriptine and L-dopa blocked the increase in serum PRL concentration but not the reduction in anterior pituitary DA content caused by reserpine, indicating that reserpine has a direct action on DA storage mechanisms in the anterior pituitary. These data suggest that the ability of DA to inhibit PRL secretion and the incorporation of DA into the anterior pituitary are not causally related.
在接受各种影响多巴胺(DA)释放、储存或作用的药物治疗的雄性大鼠中,测定了垂体前叶中多巴胺(DA)的含量、β-葡萄糖醛酸酶(溶酶体酶的标志物)的活性以及血清中催乳素(PRL)的浓度。增加垂体门脉血中DA的药物(苯丙胺、哌醋甲酯和左旋多巴)可增加DA含量,减少PRL分泌,且对溶酶体酶活性无影响。激活垂体前叶DA受体的药物(阿扑吗啡和溴隐亭)可降低血清PRL,但对DA含量或溶酶体酶活性无影响。减少垂体门脉血中DA的药物(α-甲基酪氨酸、γ-丁内酯和利血平)或阻断DA受体的药物(氟哌啶醇)可增加PRL分泌,降低DA含量和溶酶体酶活性。这些结果表明垂体前叶DA含量与PRL分泌之间没有明显关系。此外,增加垂体前叶中DA的浓度或激活DA受体并不会刺激溶酶体酶活性,但在对照动物中,溶酶体酶活性似乎受到DA的持续刺激,因为降低垂体前叶中DA的浓度或受体激活会降低β-葡萄糖醛酸酶活性。阿扑吗啡可降低α-甲基酪氨酸诱导的血清PRL升高,并防止垂体前叶DA含量和β-葡萄糖醛酸酶活性降低,这一结果证实了后一种观点。此外,用溴隐亭和左旋多巴预处理可阻断α-甲基酪氨酸和γ-丁内酯诱导的血清PRL浓度升高以及垂体前叶DA含量降低。另一方面,溴隐亭和左旋多巴可阻断血清PRL浓度升高,但不能阻断利血平引起的确垂体前叶DA含量降低,这表明利血平对垂体前叶中DA的储存机制有直接作用。这些数据表明,DA抑制PRL分泌的能力与DA进入垂体前叶的过程并无因果关系。